|Videos|April 28, 2017

More Data is Needed to Help Guide Antibiotic Prescribing Practices in Dentistry

Lauri A. Hicks, Director, Office of Antibiotic Stewardship, Centers for Disease Control and Prevention, discusses how more data is needed to provide dentists with better guidelines for prescribing antibiotics.

Lauri A. Hicks, Director, Office of Antibiotic Stewardship, Centers for Disease Control and Prevention, discusses how more data is needed to provide dentists with better guidelines for prescribing antibiotics.

Interview Transcript (slightly modified for readability)

“There are a number of reasons why dentists may need to prescribe an antibiotic, and there are certain circumstances where patients might need what we call a prophylactic dose of an antibiotic for a procedure. However, the frequency of prophylaxis has really decreased over time in terms of whether it’s needed; the data shows that, actually, prophylactic antibiotics are not needed for most conditions.

We don’t know very much about the ideal duration of therapy. In fact, guidelines for dental prescribing are quite limited and the data are needed to better guide dentists in their prescribing and durations. I think if we have that information available, then we’d be better able to guide and assess dental prescribing practices.”


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: XDR Shigella
Here is some important information around this pathogen and the intestinal infection.